176 related articles for article (PubMed ID: 35092134)
1. N-glycosylation regulates MET processing and signaling.
Saitou A; Hasegawa Y; Fujitani N; Ariki S; Uehara Y; Hashimoto U; Saito A; Kuronuma K; Matsumoto K; Chiba H; Takahashi M
Cancer Sci; 2022 Apr; 113(4):1292-1304. PubMed ID: 35092134
[TBL] [Abstract][Full Text] [Related]
2. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
[TBL] [Abstract][Full Text] [Related]
3. N-glycan on N262 of FGFR3 regulates the intracellular localization and phosphorylation of the receptor.
Hashimoto U; Fujitani N; Uehara Y; Okamoto H; Saitou A; Ito F; Ariki S; Shiratsuchi A; Hasegawa Y; Takahashi M
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130565. PubMed ID: 38244702
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of a Chinese Hamster Ovary Heparan Sulfate Cell Mutant Defective in Both Met Receptor Binding and Hepatocyte Growth Factor NK1/Met Signaling.
Cao T; Pan J; Li X; He Y; Jiang Y; Chang Y; Zhang Q; Lan Y; Wang H; Jiao W; Tian Z; Zhang L
Cell Physiol Biochem; 2018; 48(4):1480-1491. PubMed ID: 30107380
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
[TBL] [Abstract][Full Text] [Related]
8. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
9. Multiple biological responses are induced by glycosylation-deficient hepatocyte growth factor.
Fukuta K; Matsumoto K; Nakamura T
Biochem J; 2005 Jun; 388(Pt 2):555-62. PubMed ID: 15693751
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
11. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
Landgraf KE; Santell L; Billeci KL; Quan C; Young JC; Maun HR; Kirchhofer D; Lazarus RA
J Biol Chem; 2010 Dec; 285(51):40362-72. PubMed ID: 20937841
[TBL] [Abstract][Full Text] [Related]
12. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
14. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.
Holmes O; Pillozzi S; Deakin JA; Carafoli F; Kemp L; Butler PJ; Lyon M; Gherardi E
J Mol Biol; 2007 Mar; 367(2):395-408. PubMed ID: 17258232
[TBL] [Abstract][Full Text] [Related]
15. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
[TBL] [Abstract][Full Text] [Related]
16. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
17. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance
in non-small cell lung cancer].
Song S; Bi M
Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
[TBL] [Abstract][Full Text] [Related]
19. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
[TBL] [Abstract][Full Text] [Related]
20. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.
Peek M; Moran P; Mendoza N; Wickramasinghe D; Kirchhofer D
J Biol Chem; 2002 Dec; 277(49):47804-9. PubMed ID: 12372819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
